Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.
Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent and allogeneic cellular medicines aimed at treating a range of diseases. They can potentially be used to replace missing enzymes for patients living with certain rare enzyme deficiencies, kill tumors in cancer and regulate the immune system for the treatment of autoimmune diseases.
The U.S. Food and Drug Administration cleared the Investigational New Drug application (IND) for our first clinical candidate, RTX-134, for the treatment of phenylketonuria. Additionally, we plan to file an IND by early 2020 for our lead cancer program, RTX-240 (formerly RTX-212), for the treatment of solid tumors. In total, we plan to file four to five INDs in 2019 and 2020.